吉西他滨联合白蛋白结合型紫杉醇治疗晚期胰腺癌的疗效及安全性  

Efficacy and safety of gemcitabine combined with albumin-bound paclitaxel in the treatment of advanced pancreatic cancer

作　　者：翟鹏涛 李梅 庞宏涛 ZHAI Pengtao;LI Mei;PANG Hongtao(Invasive Technology Department,Shaanxi Provincial Cancer Hospital,Xi’an 710061,Shaanxi,China;Department of Medical Oncology,Shaanxi Provincial Cancer Hospital,Xi’an 710061,Shaanxi,China)

机构地区：[1]陕西省肿瘤医院介入科,西安7100610 [2]陕西省肿瘤医院肿瘤内科,西安7100610

出　　处：《癌症进展》2021年第6期619-622,共4页Oncology Progress

摘　　要：目的探讨吉西他滨联合白蛋白结合型紫杉醇治疗晚期胰腺癌的临床疗效及安全性。方法根据治疗方式的不同将105例晚期胰腺癌患者分为对照组(n=49)和观察组(n=56),对照组患者采用吉西他滨治疗,观察组患者采用吉西他滨联合白蛋白结合型紫杉醇治疗。比较两组患者的临床疗效、肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、甲胎蛋白(AFP)]水平、生存情况及不良反应发生情况。结果观察组患者的总有效率和疾病控制率分别为58.93%和78.57%,分别高于对照组的38.78%和57.14%,差异均有统计学意义(P﹤0.05);观察组中TNM分期为Ⅲ期和Ⅳ期患者的总有效率分别为61.29%和56.00%,与对照组的40.91%和37.04%比较,差异均无统计学意义(P﹥0.05);观察组中有转移和无转移患者的总有效率分别为56.52%和60.61%,与对照组的33.33%和44.00%比较,差异均无统计学意义(P﹥0.05)。治疗后,观察组患者的血清CEA、CA19-9及AFP水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组和对照组患者的中位生存期分别为9.9个月和8.1个月。观察组患者的9个月、12个月生存率均高于对照组,差异均有统计学意义(P﹤0.05)。观察组和对照组患者的3~4级不良反应总发生率分别为26.79%和32.65%,差异无统计学意义(P﹥0.05)。结论吉西他滨联合白蛋白结合型紫杉醇治疗晚期胰腺癌患者的临床疗效及安全性均较好。Objective To investigate the clinical efficacy and safety of gemcitabine combined with albumin-bound paclitaxel in the treatment of advanced pancreatic cancer.Method According to different treatment methods,105 patients with advanced pancreatic cancer were divided into control group(n=49)and observation group(n=56).Patients in the control group were treated with gemcitabine,while patients in the observation group were treated with gemcitabine combined with albumin-bound paclitaxel.The clinical efficacy,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),alpha-fetoprotein(AFP)]levels,survival and adverse reactions were compared between the two groups.Result The total effective rate and disease control rate of patients in the observation group were 58.93%and 78.57%,respectively,which were higher than those in the control group(38.78%and 57.14%,respectively),and the differences were statistically significant(P<0.05).The effective rates of patients with TNM stage Ⅲ and Ⅳ in the observation group were 61.29%and 56.00%,respectively,and there was no significant difference compared with the control group(40.91%and 37.04%)(P>0.05).The effective rates of patients with and without metastasis in the observation group were 56.52%and 60.61%,respectively,and there was no significant difference compared with the control group(33.33%and 44.00%)(P>0.05).After treatment,the levels of serum CEA,CA19-9 and AFP in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The median survival time of patients in observation group and control group was 9.9 months and 8.1 months,respectively.The 9-month and 12-month survival rates of patients in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of 3-4 grade adverse reactions in the observation group and the control group was 26.79%and 32.65%,respectively,with no significant difference(P>0.05).Conclusi

关 键 词：吉西他滨 白蛋白结合型紫杉醇 晚期胰腺癌 肿瘤标志物 

分 类 号：R735.9[医药卫生—肿瘤]